Shares of Nuformix plc (LON:NFX – Get Free Report) dropped 10% on Tuesday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 417,744 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 10,412,084 shares. The stock had previously closed at GBX 0.05 ($0.00).
Nuformix Price Performance
The stock has a market cap of £409,655.00, a P/E ratio of -1.63 and a beta of 1.22. The business has a 50 day simple moving average of GBX 0.05 and a 200-day simple moving average of GBX 0.11. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- What is the MACD Indicator and How to Use it in Your Trading
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Best Stocks Under $10.00
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Smart Picks: Discounted Stocks for Savvy Investors
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
